GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (STU:TQ80) » Definitions » Net Cash per Share

Theratechnologies (STU:TQ80) Net Cash per Share : €-1.00 (As of Aug. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Theratechnologies Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Theratechnologies's Net Cash per Share for the quarter that ended in Aug. 2024 was €-1.00.

The historical rank and industry rank for Theratechnologies's Net Cash per Share or its related term are showing as below:

STU:TQ80's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.36
* Ranked among companies with meaningful Price-to-Net-Cash only.

Theratechnologies Net Cash per Share Historical Data

The historical data trend for Theratechnologies's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Net Cash per Share Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.45 -3.35 -2.25 -3.35 -1.17

Theratechnologies Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.86 -1.17 -1.17 -1.15 -1.00

Competitive Comparison of Theratechnologies's Net Cash per Share

For the Biotechnology subindustry, Theratechnologies's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Price-to-Net-Cash falls into.



Theratechnologies Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Theratechnologies's Net Cash per Share for the fiscal year that ended in Nov. 2023 is calculated as

Net Cash per Share (A: Nov. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(37.318-91.142-0)/45.98
=-1.17

Theratechnologies's Net Cash per Share for the quarter that ended in Aug. 2024 is calculated as

Net Cash per Share (Q: Aug. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(35.245-81.076-0)/45.98
=-1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies  (STU:TQ80) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Theratechnologies Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Theratechnologies Headlines

No Headlines